IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Flu

Article

The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.

"BARDA is supporting an important expansion of IDRI's technology to solutions that address neglected diseases as well as those that affect us all in the United States," says Dr. Darrick Carter, director of formulations at IDRI and principal investigator on the BARDA influenza contract. Adjuvants and other immunostimulants can improve the body's immune response to diseases like influenza, in turn, reducing the amount of vaccine needed for protection (dose-sparing). The use of adjuvants will allow for expansion of vaccine supply to meet the necessary global demands during a pandemic.

BARDA is within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The project is part of the innovations portfolio awarded out of BARDA's Strategic Science and Technology Division's Innovation BAA (Broad Agency Announcement).

Adjuvants are compounds used to improve the body's immune response to vaccines. Adjuvant technology is proving invaluable in the development of vaccines for serious diseases for which vaccines are not currently available, including malaria and HIV.

Adjuvants are a key research component of IDRI's malaria, tuberculosis, leishmaniasis and leprosy vaccine development programs supported by the Bill and Melinda Gates Foundation, the National Institutes of Health, and the American Leprosy Missions.

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty.

Related Videos
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Related Content